News
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...
The FDA has approved Sanofi and Regeneron’s Dupixent as a treatment for adults with bullous pemphigoid, a rare chronic autoimmune skin condition that causes severe itching, painful blisters and open ...
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...
Stocktwits on MSN2d
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays DullRegeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...
AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.
Pharmaceutical Technology on MSN2d
DoH – Abu Dhabi and Sanofi link for vaccine developmentAbu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local ...
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback